Expert Financial Analysis and Reporting

Report Overview This blog gives a quick update on my thinking on the 15 stocks which I cover. In most cases, it just offer my opinion with a few supporting thoughts and provides a link to more extensive articles. Also, the reports section of my website has other in-depth reports that you may want to […]

Purpose of This Report This report is being written at a time of panic in the market in which a sharp drop in the stock market indices has set off a much steeper plunge in the stock prices of emerging biotechnology companies which are the focus of SmithOnStocks. In this volatile and depressing environment, there […]

Purpose of Report I am leaving on vacation and will be back on August 27, 2015; you won’t hear from me until then. As the second quarter conference calls and accompanying updates are almost behind us, I thought I would provide a quick summary of where I stand on the15 companies I cover. These are […]

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

SmithOnStocks Mailbox April 28, 2015 A Quick Take on Recent Events If you have a question for the mailbox, contact me. Purpose of this Note I have written extensively on Antares, Agenus, Cytokinetics and Discovery Laboratories. I have Buys on Antares, Agenus and Cytokinetics. I have a Hold on Discovery (what a troubled history), but […]

Introduction A number of subscribers have suggested that I write more on recent news events that relate to companies that I follow. This note is in response to these requests giving my take on some recent news releases. I would appreciate your feedback on whether this is of any value to you. I am considering […]

Overview This has been a tough year for many small emerging biotechnology firms. Many have been in a bear market while the market as a whole had a reasonable year. The group did very well in 2013 and early 2014 and kept pace with strong price performance by the larger biotechnology companies. In March of […]

This Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology has had a major impact on the small biotechnology names that I specialize in. The correction has been stomach churning for me even though I have been through this many times before. I am […]

Mallinckrodt (MNK) announced that one of its subsidiaries will start a tender offer to acquire all of the outstanding shares of Cadence for $14.00 per share. This represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals, Inc. The transaction is expected to close in mid […]